Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II ascending multi-dose study of BMS-663513 (agonistic anti-CD137) in advanced solid tumors and malignant melanoma
2007-000416-91Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of urelumab in Non-hematologic malignancy and melanoma, sponsored by Bristol Myers Squibb. Primary endpoint: Primary safety outcome measures. Started Jun 2007; status: completed.
02
Drugs
urelumab
03
Conditions
Non-hematologic malignancymelanoma
Beyond the preview
Go deeper on 2007-000416-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000416-91.